There is need to do the India specific development of such tests. That is another challenge. Another issue is that the clinical validation is required and due to issues in regulatory setup, the discouragement happens within the companies who are developing such products.
The biotech industry needs to engage the medical community who generally say that they have lot of patient load and can’ t participate in such exercises. They need to be convinced. The non communicable disease such as diabetes, cardiovascular diseases need solutions that should work for life. The government must steer the capacity strategies to ensure that the communities that are working for clinical validation get support. Ownership of the clinical trials is a must. For few patients who have no access to early products, the clinical trials are seen as a hope. The compassionate use selectively is fine.
In terms of discovery or development of molecules, it would be interesting that if Indian groups take advantage of the international funds.
Even if it is risky, it might give at least a clue if not a product. There is also a need to utilize the vast traditional knowledge to create new chemical or biological entities.
The key is to find innovative ways of generating ideas through vast network of institutes, take them to industry and get the best answer possible.
BIOVOICENEWS. COM 49